

EXPRESS MAIL CERTIFICATE

Date 6/24/99 Label No. 595860054

I hereby certify that, on the date indicated above, I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

Jc530 U.S. PTO
09/344189
06/24/99

Docket No. 0342/1D888US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charles E. ROGLER

For: CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL
HEPATOCELLULAR CARCINOMA IN MOUSE REPOPULATED LIVERS

CONTINUING APPLICATION

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

This is a request for filing under 37 C.F.R. 1.53(b) of a:

☒ Continuation-in-Part ☐ Divisional

application of the following pending prior application:

Serial No. 09/156,892

Filed: 09/18/98

Of: Charles E. ROGLER

For: CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL HEPATOCELLULAR
CARCINOMA IN MOUSE REPOPULATED LIVERS

Examiner:

Group: 1632

1. The filing fee is calculated below:

CLAIMS AS FILED, AFTER ACCOMPANYING AMENDMENT

	Claims on File	Number Extra	Rate
Basic Fee			\$760.00
Total Claims	36 - 20 =	16 x \$18	\$288.00
Independent Claims	4 - 3 =	1 x \$78	\$78.00
If Multiple Dependent Claims Are Present, Add \$260.00			\$0.00
Total Filing Fee			\$1,126.00
For Small Entity (half of preceding total)*			\$

*No. 9 below must be checked to claim this reduction.

2. A check in the amount of \$ ____ is enclosed.
3. ☐ Cancel claims.
4. ☒ Amend the specification by inserting before the first line the sentence (check one and fill in):

 "This is a continuation-in-part of application Serial No. 09/156,892, filed September 18, 1998. Each of these prior applications is hereby incorporated herein by reference, in its entirety."
5. ☒ The prior application is assigned to: Albert Einstein College of Medicine of Yeshiva University
6. ☒ An unexecuted Declaration is also enclosed.
7. ☒ Informal Drawings are filed herewith (6 sheets; Figs. 1-6B)
8. ☐ A verified statement claiming small entity status (check one):
☐ was filed in parent application or ☐ is enclosed.
9. ☐ Priority is claimed from
 Country:
 Number:

Docket No. 0342/1D888-US1

Date:


The priority document

☐ was filed in the prior application
☐ is enclosed.

10. The Assignment

☒ was recorded at Reel 9583 Frame 0423 on 11/12/98
☐ is enclosed.

Respectfully submitted,



Anne E. Zitron, Ph.D.

Reg. No. 41,391

Agent of Record in Prior Application

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022
212-527-7700

::ODMA\WORLD\OX\M:\0342\0D888\KRJ2857.WPD

EXPRESS MAIL CERTIFICATE

Date 6/24/99 Label No. 595860054

1

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington D.C. 20231 by "Express Mail Post Office to Addressee" service.

0342/1D888-US1

DB Beck DB Beck
Name (Print) Signature

5

**CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL HEPATOCELLULAR
CARCINOMA IN MOUSE REPOPULATED LIVERS**

This is a continuation-in-part of application Serial
No. 09/156,892, filed September 18, 1998 which is hereby
incorporated herein by reference, in its entirety.

This invention was made with Government support under
U.S. Public Health Service Grant Nos. CA 37232 and DK 46952.
The Government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention pertains to chimeric mice
repopulated with xenogenic mammalian hepatocytes which can be
infected with at least one compatible mammalian hepatitis
virus. The invention also pertains to methods of making such
mice and to methods of using the chimeric mice in the study of
viral replication, hepatocellular carcinoma and treatment of
these conditions.

BACKGROUND OF THE INVENTION

[Within this application several publications are
referenced by Arabic numerals within parentheses. Full
citations for these references, listed in sequence, may be
found at the end of the specification. All of the cited
references are incorporated by reference in their entirety.]

Hepatitis B virus (HBV) infection remains a major
health problem with more than 350 million chronic HBV carriers
worldwide who are at risk for developing liver cirrhosis and
hepatocellular carcinoma (HCC) (1, 2, 3, 4). The development
of effective therapies for eradicating HBV in chronic carriers

has been limited by an incomplete understanding of the mechanisms of viral persistence (5).

HBV is a member of the hepadnavirus family of mammalian hepatitis viruses. HBV is a human virus which can also infect other primates, such as chimpanzee, as well as human hepatocellular carcinoma cells, such as HepG2 and Huh7. Other hepadnaviruses include Woodchuck Hepatitis Virus (WHV) which is native to the woodchuck *Marmotta monax* and can also infect the ground squirrel, as well as the Ground Squirrel Hepatitis Virus (GSHV) which infects the ground squirrel. Avian hepadnaviruses have been isolated from the duck (DHBV) and the heron (HHBV). In addition to the hepadnaviruses, there are other hepatitis viruses including, for example, Hepatitis A, C, E and F viruses, as well as Hepatitis Delta which requires the presence of Hepatitis B as a helper virus.

Interferon-alpha is the only currently approved treatment for persistent HBV infection (5, 6, 7). Besides exhibiting various immunomodulatory effects (8), interferon-alpha induces the release of intracellular enzymes such as 2'5'-oligoadenylate synthetase and double-stranded RNA-dependent protein kinase, which degrade viral messenger RNAs and inhibit viral protein synthesis (8) *in vitro* (9) and *in vivo* (6, 10). Patients who respond to interferon-alpha therapy show a decrease in circulating HBV DNA levels within the first week (8).

Both humoral and cellular elements of the host immune response are important for HBV clearance. The humoral response to HBV antigens, i.e. antibodies to hepatitis B surface antigen (anti-HBs), helps clear circulating virions and confers protection against reinfection, whereas T cell-mediated responses eliminate infected host cells (11, 12). HBV transgenic mice have been developed which replicate wild type HBV under the control of a full length HBV transgene inserted into the mouse genome. Recent work using these HBV transgenic mice has shown that this replication process can be altered by

murine cytokines, such as tumor necrosis factor alpha and interferon gamma. These cytokines have the capacity to downregulate HBV replication in a noncytopathic manner (13, 14). It is therefore of interest to determine whether hepatitis virus replication will become persistent in the absence of B and T cells in the host, and whether acute infection of hepatocytes, in such an environment, would lead to viral persistence in all or some cases.

HBV transgenic mice have provided important new information regarding viral pathobiology (11, 12, 13, 14). However, HBV replication in these mice does not occur by an identical mechanism to that which occurs in naturally infected hepatocytes. In the transgenic HBV mice, replication is driven by an integrated transgene in the mouse chromosome. As a result, the hepatocytes can never be completely "cured" of their HBV genomes. In contrast, in hepatocytes which are natural hosts for hepatitis virus infection, replication is normally maintained by a population of episomal covalently closed circular (ccc) viral DNA molecules in the hepatocyte nuclei. These molecules have a limited half life and do not replicate in the nucleus. Therefore, natural host hepatocytes are capable of being completely "cured" of viral DNA. Thus, it would be highly desirable to obtain a system whereby this characteristic of natural host cells could be employed in antiviral testing, since a complete "cure" is possible and could be screened for.

Recently, advances have been made in mouse liver repopulation with transplanted rat hepatocytes (15). In addition, a hepatocyte-lethal phenotype has been discovered in urokinase-type plasminogen activator (uPA) transgenic mice and such mice have been shown to be capable of liver replacement with xenografted rat hepatocytes (16, 17, 18). Such replacement of the mouse liver with xenogenic rat hepatocytes is facilitated in a uPA mouse because uPA transgene expression places these hepatocytes at a growth disadvantage compared with

nontransgenic hepatocytes (16). Transplanted hepatocytes in this system are thus selectively amplified in a mixed polyclonal pattern. A disadvantage of this system is that the rat cells are not natural hosts for hepadnaviruses and cannot be infected by natural mechanisms with any of the known hepadnaviruses. It would thus be advantageous to have a method for repopulating the liver parenchyma of many mice with xenogenic mammalian hepatocytes capable of being infected with hepadnaviruses and derived from a single donor, thus creating mice with chimeric livers that contain genetically identical hepatocytes.

The recent isolation of a Severe Combined Immune Deficiency (SCID) mouse which is homozygous for the Recombination Activation Gene 2 (RAG2) knockout mutation provides a mouse deficient in both B and T immune cells (22). This immunetolerant mouse is not capable of rejecting xenogenic tissue.

The woodchuck animal model provides for the study of woodchuck hepatitis virus (WHV) infection in a natural host setting which mimics infection of human liver with HBV (19, 20, 21). One disadvantage of the woodchuck is that it is a relatively inaccessible, genetically heterogeneous animal which is difficult to breed and maintain in a laboratory setting. It would be highly desirable to obtain a model system for hepadna and other hepatitis viral infection in an animal that is both easy to breed and maintain, as well as being genetically controlled and cost effective.

It would be highly desirable to obtain a convenient animal model system for the observation of hepatitis virus replication and development in host hepatocytes that can be infected by natural means. Indeed, it would be highly desirable to use the above model to test the effects of drugs potentially active against hepatitis virus replication, development of hepatocellular carcinoma and treatments for such. A variety of treatments for diseases resulting from

hepatitis virus infection could be tested in such an animal model system.

SUMMARY OF THE INVENTION

5 In one aspect, the invention provides a method of making a chimeric mouse by creating an immunetolerant mouse which has a degenerated liver, and repopulating the degenerated liver parenchyma by transplanting xenogenic mammalian hepatocytes capable of growing and being infected with at least one compatible mammalian hepatitis virus.

10 The xenogenic mammalian hepatocytes used to repopulate the chimeric mice can be infected prior to their use in transplantation or following repopulation.

15 A further aspect of the invention provides a chimeric mouse model system comprising an immunetolerant mouse which has a degenerated liver repopulated with xenogenic hepatocytes capable of growing and being infected with compatible mammalian hepatocytes.

20 In yet another aspect, the invention provides a method for screening anti-viral activity of a test compound comprising administering said test compound to the chimeric mouse of the invention which has been infected with at least one compatible mammalian virus and assaying the level of replication of the virus in said mice.

25 A still further aspect of the invention provides a method for screening anti-cancer activity of a test compound comprising administering said test compound to the chimeric mouse of the invention which has been infected with at least one compatible mammalian hepatitis virus and assaying the mice for the development of hepatocellular carcinoma in said mice.

30 A preferred immune tolerant mouse with degenerated liver is hemizygous or homozygous for the urokinase-type plasminogen activator (uPA) transgene and is homozygous for the Recombination Activation Gene 2 (RAG-2) knockout gene. Such a mouse is herein designated as a uPA/RAG2 mouse. A preferred

xenogenic hepatocyte is a woodchuck hepatocyte and a preferred compatible hepatitis virus is the Woodchuck Hepatitis Virus (WHV).

A particularly preferred xenogenic hepatocyte is a primate hepatocyte and a particularly preferred compatible hepatitis virus is the human hepatitis A virus, human hepatitis C virus, human hepatitis D virus coinfecting with hepadnavirus, human hepatitis E virus, human hepatitis F virus or human hepadnavirus.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a photograph depicting the migration pattern of mouse (lane 1) and woodchuck (lane 2) serum albumin in a Coomassie Blue stained gel. Serum from a chimeric uPA/RAG-2 mouse containing woodchuck hepatocytes is shown in lane 3. Bands in the position of both mouse and woodchuck albumin are a diagnostic marker for the presence of functional woodchuck hepatocytes in the chimeric mouse.

Figs. 2 (A)-(E) comprise photographs of gels that depict the presence of woodchuck genomic DNA and WHV DNA plus the WHV X (WHx), Core (WHc) and envelope (WHs) proteins in the liver of uPA/RAG-2 mice transplanted with WHV-positive woodchuck hepatocytes. Fig. 2(A) depicts a Southern blot of chimeric mouse liver genomic DNAs hybridized with a woodchuck genome DNA probe. Fig. 2(B) depicts a Southern blot showing WHV DNA forms, detectable in uPA/RAG-2 mouse genomic liver DNA, hybridized with a WHV DNA probe. Fig. 2(C) depicts a Western blot of uPA/RAG2 chimeric mouse liver extracts detection. WHx using an anti-WHx antibody. Fig. 2(D) As in 2(C) but detecting WHc using an anti-WHc antibody. Fig. 2(E) As in 2(C) but detecting WHs using an anti-WHs antibody.

Figs. 3 (A) and (B) comprise photographs which depict histological studies of cryostat sections from WHV-infected

chimeric mice. Fig. 3(A) depicts detection of WHcAg in a uPA/RAG-2 mouse liver containing WHV-positive woodchuck hepatocytes by immunostaining with a WHc-antiserum. Woodchuck hepatocytes infected with WHV have specific red immunofluorescent signals not present in mouse cells. Fig. 3(B) depicts DPPIV staining of bile canaliculi (200x) in uPA/RAG-2 mouse liver containing woodchuck hepatocytes.

Fig. 4 is a graph depicting the effect of interferon-alpha and dexamethasone upon the titer of WHV in the blood of chimeric uPA/RAG-2 mice transplanted with woodchuck hepatocytes.

Figs. 5(A)-(H) is a series of photographs which depict H&E staining of liver sections. Figs. 5(A), 5(C), 5(E), and 5(G) depict staining of livers from a donor woodchuck. Figs. 5(B), 5(D), 5(F), and 5(H) depict staining of liver sections from a UPA/RAG-2 chimeric mouse after repopulation with WHV-positive woodchuck hepatocytes from the donor woodchuck liver depicted in 5A,C,E, and G.

Figs. 6(A) and (B) are photographs of Southern blots. Fig. 6(A) depicts a Southern blot analysis of DNA of a tumor which developed in a uPA/RAG-2 chimeric mouse liver. The tumor DNA hybridized with both a woodchuck genomic DNA probe (lane 3) and a viral WHV DNA probe (lane 4). Fig. 6(B) depicts Southern blot analysis of tumor DNAs from HCCs present in the original donor woodchuck liver used to make the chimeric liver analyzed in 6A.

DETAILED DESCRIPTION

The present invention provides a chimeric mouse liver model system for mammalian hepatitis. The chimeric mouse liver model is for use in studying hepadnavirus (hepatitis B virus) infection, as well as other hepatitis virus infection and in developing methods for preventing and treating diseases developing from such infection.

The chimeric mice of the invention are generated by repopulating the degenerated liver parenchyma of immunetolerant mice by transplanting xenogenic mammalian hepatocytes capable of being infected with at least one compatible mammalian hepatitis virus. When used as a model system for hepatitis, the xenogenic mammalian hepatocytes can be infected prior to transplantation or following repopulation.

"Degenerated liver" as used herein is a diseased liver having compromised biochemical function which leads to either hepatocyte death and/or an inability to replicate. Mouse genes or mutations which lead to a degenerated liver include, but are not limited to, the presence of the uPA transgene and to limitations in the uPA gene.

"Chimeric" as used herein is the transplanted degenerated mouse liver which is composed of parts that are of different origin from the native mouse liver cells.

"Immunetolerant" as used herein is defined as an animal such as a mouse which is deficient in B and T cells. Examples of mice which are immunetolerant are nude mice, RAG2 knockout mice, RAG1 knockout mice, and SCID mice.

"Transplanting" as used herein is the process of transferring isolated xenogenic mammalian liver derived cells into the immunotolerant mouse which has a degenerated liver. Said liver cells consist of a great majority (generally greater than 75%) of primary hepatocytes. Other cells which are transplanted along with the hepatocytes may include endothelial cells, ito cells and kupfer cells.

"Repopulating" as used herein is the process by which the transplanted liver cells are incorporated into the recipient liver parenchyma and grow, replacing the native degenerated host liver parenchyma.

Xenogenic mammalian hepatocytes can be transplanted into degenerated mouse livers via a number of methods. These include splenic injection or direct portal vein injection. A preferred method of transplantation is via splenic injection

(15). Transplanted hepatocytes grow as microclones in the recipient liver from a common donor source and their growth pattern generally restores a normal cord structure in the liver.

5 The xenogenic mammalian hepatocytes of the invention can be derived from any desired source because the immunetolerant mouse will have no B and T cells and are incapable of eliciting an immune response to xenogenic cells. Sources for xenogenic mammalian hepatocytes for use in the
10 present invention include, but are not limited to, human, chimpanzee, baboon, woolly monkey, ground squirrel, and woodchuck hepatocytes. Preferred xenogenic mammalian hepatocytes of the invention are hepatocytes from the woodchuck (*i.e.*, *Marmotta monax*).

15 Particularly preferred xenogenic hepatocytes of the invention are primate hepatocytes selected from the group consisting of human, chimpanzee, baboon and hepatocytes isolated from primates capable of supporting the replication of human hepatitis viruses.

20 The xenogenic mammalian hepatocytes of the invention can be infected with at least one compatible mammalian virus.

 The xenogenic primate hepatocytes of the invention can be infected with at least one compatible human hepatitis virus.

25 "Compatible" as used herein refers to any virus which is capable of replicating and developing in the xenogenic mammalian hepatocytes. Examples of compatible mammalian viruses include, but are not limited to, hepatitis A virus, hepatitis C virus, hepatitis delta virus coinfecting with
30 hepadnavirus, hepadnavirus (hepatitis B virus), human hepatitis B virus, ground squirrel hepatitis virus, woodchuck hepatitis virus, hepatitis E virus and hepatitis F virus.

 Particularly preferred compatible hepatitis viruses are human hepatitis viruses, including, but not limited to
35 human hepatitis A virus, human hepatitis B virus and human

hepatitis C virus, human hepatitis delta virus coinfecting with hepadnavirus, human hepatitis E virus and human hepatitis F virus.

When woodchuck hepatocytes are used as the xenogenic mammalian hepatocytes, woodchuck hepatitis virus (WHV) replication is supported indefinitely.

Examples of mammalian hepadnavirus and hepatocyte combinations can be found in Table 1.

TABLE 1

Mammalian Hepadnaviruses and Their Hosts

Virus	Natural Host	Other Hosts and Cells to be Infected
Hepatitis B (HBV)	Human	Chimpanzee, baboon, HepG2 and Huh7 Hepatocellular carcinoma cells
Woodchuck Hepatitis (WHV)	Woodchuck (<i>Marmotta Momax</i>)	Ground squirrel
Ground Squirrel Hepatitis (GSHV)	Ground Squirrel	Woodchuck
Wooly Monkey Hepatitis (WMHV)	Wooly Monkey	NOT AVAILABLE

A preferred chimeric mouse of the invention is generated by repopulating the degenerated liver parenchyma of an immunetolerant mouse which is hemizygous or homozygous for the urokinase-type plasminogen activator (uPA) transgene and is homozygous for the Recombination Activation Gene 2 (RAG-2) which is a knockout gene.

The RAG2 mice are immunetolerant because they lack the ability to produce mature, functional B or T cells. The expression of the uPA transgene in the native hepatocytes of the uPA transgenic mice causes them to undergo pathological changes involving alterations of their membranes which block important metabolic functions and block their cell division. These alternations cause a great many hepatocytes to die. This pathology is due to an excessive amount of uPA production by the hepatocytes, however, the uPA produced in these mouse hepatocytes does not block the growth of transplanted hepatocytes which do not contain the transgene.

The liver parenchyma of the uPA/RAG-2 mouse is repopulated with xenogenic mammalian hepatocyte such that the liver containing the xenogenic cells is chimeric. This chimeric uPA/RAG2 mouse can then be infected with compatible mammalian hepatitis virus.

The uPA/RAG-2 mice are generated by:

a. crossing a hemizygous or homozygous urokinase-type plasminogen activator (uPA) transgenic mouse with a homozygous Recombination Activation Gene 2 (RAG-2) knockout mouse to generate F1 uPA hemizygous, RAG-2 hemizygous sibling mice; and

b. crossing F1 sibling mice to each other in sibling matings or backcrossing the F1 mouse to a RAG2 homozygote, to generate F2 uPA hemizygous or homozygous, RAG2 homozygous (uPA/RAG2) mice.

F2 mice can also be sibling mated to generate

additional uPA/RAG2 F3 mice.

Following transplantation, the xenogenic mammalian hepatocytes repopulate the degenerated uPA/RAG-2 liver parenchyma, and become integrated into it, replacing up to 90% of the uPA/RAG-2 mouse hepatocytes.

The chimeric mouse model system of the invention makes it possible to study hepatitis virus replication both in rapidly proliferating hepatocytes during liver repopulation and in quiescent hepatocytes after completion of liver regeneration. The chimeric mouse system combines several desirable characteristics of previous animal models for studying hepatitis virus infection and pathogenesis.

The chimeric mice of the invention also provide a system in which to study mechanisms of viral persistence in natural host hepatocytes in the absence of B and T cell-mediated immune responses. The absence of B and T cells in these mice provides for immune tolerant mice which do not develop liver disease upon infection with hepatitis virus. The absence of B and T cells, and thus immune responses, in these mice provides a system whereby the liver is not degraded or degenerated upon infection. The system thus makes it possible to test compounds which inhibit viral replication in a controlled environment, in the absence of actual liver disease.

The absence of B and T cells in the chimeric mice of the invention also provides an opportunity for their replacement with specific xenogenic or mouse immune system

cells selected for specific B or T cell functions. The xenogenic cell type is selected based upon the type of xenogenic mammalian hepatocytes with which the chimeric mice are repopulated. If woodchuck cells are the donor cells then woodchuck or mouse immune system cells are selected.

When the xenogenic mammalian hepatocytes have been infected with compatible mammalian hepatitis virus, the chimeric mouse model system of the invention can be used to study the replication of hepatitis virus and the development of hepatocellular carcinoma (HCC) disease states. The infected chimeric mice also provide a system in which to monitor the effects of antiviral and anticancer drugs. The mice can be used in a method to screen and identify treatments for chronic hepatitis virus infection in mammals by evaluating the efficacy of drugs which effect replication. The mice can also be used in a method to screen and identify chemotherapeutic treatments for malignant hepatic cancers and precancerous tissue in such mice, as well as in a method to screen for anticancer agents which prevent the development of hepatocellular carcinomas in such mice.

The development of hepatocellular carcinoma progresses from normal hepatocytes through a number of stages. These include 1) precancerous hyperplasia where the cells exhibit extra growth; 2) altered hepatic foci, where precancerous lesions are amplified; 3) neoplastic nodules; 4) adenoma or benign tumors which at late stages may exhibit early malignancy; and 5) malignant cancerous tumors or hepatocellular

carcinomas.

The basic steps in using this model to test antiviral compounds include (1) characterizing the level of hepadnavirus DNA in the blood of the mouse before treatment begins; (2) injecting various doses of the test compound into the mouse (intraperitoneally, intramuscularly or intravascularly) at various intervals (daily, weekly etc); (3) analyzing the blood of the mice for a reduction in viral titre; (4) analyzing the liver of the mice for curing or reduction of the viral DNA (ie. removal of viral closed circular covalent DNA); (5) ceasing treatments and determining if there is a recurrence of viral replication.

Antiviral agents can be tested in the chimeric mouse model system of the invention for their effectiveness in clearing molecular species of hepatitis viral DNA. Among the antiviral agents that can be tested in the mouse model of the invention are the interferons (α , β , γ , etc.), cytokines (interferons, tumor necrosis factor alpha, FN, F α , IL1-13, etc.), all growth factors (TGF β , EGF, TGF α , etc.), hormones (glucocorticoids, insulin, growth hormone, etc.), nucleoside analogues (3TC, etc.), and antisense DNA/RNA. However, the system is not limited to testing these agents and virtually any agent believed to have antiviral activity can be tested with the chimeric mouse model system of the invention.

In addition to testing the antiviral agents, in the chimeric mouse model system of the invention, these agents can also be also tested as anticancer agents. However, the system

is not limited to testing these agents and virtually any agent believed to have anticancer activity can be tested with the chimeric mouse model system of the invention. Tests for the activity of anticancer agents are carried out similarly to those for anti-viral testing, except that for testing the prevention of cancer, the mice are allowed to live a longer time, (up to a year or two) in order to observe the occurrence of cancer. In addition, treatment with the potential anti-cancer drug would be discontinued in some animals to determine whether there was reoccurrence of the tumor. Tests for chemotherapeutic agents would be carried out as above, except that mice with malignant cancerous tissue (i.e., tumors) or precancerous tissue would be used and the amelioration of the malignant cancerous tissue or the prevention of the development of cancerous tissue from precancerous tissue is monitored.

In all of the tests for antiviral or anti-cancer compounds, control mice are used for comparison. Control mice are those that are identical to test mice except that no compounds are administered.

A major objective for hepatocarcinogenesis studies is to define the cellular and molecular phenotype of precancerous hepatocytes in order to design early diagnostic and intervention protocols. The straightforward identification of amplified precancerous lesions called altered hepatic foci (AHF), provides a tool for studying genetic changes in hepatocytes derived from precancerous lesions. Such identification can be carried out through analysis and

identification of unique hepatocyte phenotypes present in AHFs. The AHF hepatocytes have large nuclei and prominent nucleoli. The clonality and origin of the lesions can be determined through analysis of viral DNA integration patterns in both the donor mammalian liver and in the transplanted mammalian hepatocytes in the chimeric mouse liver. In addition, the clonal potential of donor liver tumor cells derived from chronic hepatitis virus carrier donors can be determined in the chimeric mice.

The presence of unique hepatitis virus DNA integrations in HCCs which arise in the chimeric mouse liver demonstrates that an *in vivo* selection and clonal expansion of the xenogenic mammalian hepatocytes has taken place. This activity suggests that tumor progression occurs following cell transplantation. Such clonal expansion of the xenogenic mammalian hepatocytes provides sufficient quantities of transformed cells to investigate and better understand the roles of viral genes and hepatitis virus DNA integrations in the multistep progression to HCC and can be applied to the analysis of any type of xenogenic mammalian hepatocyte/compatible mammalian hepatitis virus combination of the invention.

The following examples are intended to illustrate but not limit the present invention.

Example 1

GENERATION OF CHIMERIC MICE**Animals**

uPA mice were obtained from Jackson Laboratories (Bar Harbor, Maine), RAG-2 knockout mice from Taconic Farms (Germantown, New York), and adult woodchucks from either North Eastern Wildlife (South Plymouth, New York), or Cornell University (Ithaca, New York). Animals were housed and maintained under specific pathogen-free conditions in accordance with NIH guidelines. One uninfected woodchuck was utilized, which was negative for all WHV markers, and three infected woodchucks were utilized which all had persistent WHV infections and were woodchuck hepatitis virus surface antigen (WHsAg) and anti-woodchuck hepatitis virus core antibody (anti-WHc) positive.

Generation of Tolerant uPA/RAG-2 Mice

Hemizygous urokinase-type plasminogen activator (uPA) transgenic mice were crossed with homozygous Recombination Activation Gene 2 (RAG-2) knockout mice to generate F1 uPA hemizygous, RAG-2 hemizygous sibling mice. These F1 sibs were then backcrossed to homozygous RAG2 knockout mice to generate F2 uPA hemizygous or homozygous, RAG2 homozygous (uPA/RAG2) mice for use in hepatocyte transplantation/liver repopulation experiments. In addition, the F1 mice were, in some cases, sibling mated to derive the desired uPA/RAG2 F2 mice. The F2

sibs were also backcrossed to generate additional uPA/RAG2 F3 mice.

The uPA transgene was identified by polymerase chain reaction (PCR) of mouse-tail DNA with the following nucleotide sequences: Primer 1: 5'-CATCCCTGTGACCCCTCC-3' (SEQ ID NO. 1),
Primer 2: 5'-CTCCAAACC ACCCCCCTC-3' (SEQ ID NO. 2). Homozygous uPA transgenic mice were distinguished from hemizygous mice by PCR as previously reported (18). For the embodiments described herein, both homozygous and hemizygous uPA mice were used. The RAG-2 knockout mutant gene was identified by PCR analysis of tail DNA as previously described (23).

Isolation and Transplantation of Woodchuck Hepatocytes

WHV-infected woodchuck hepatocytes were isolated by the two-step in situ collagenase perfusion method followed by differential centrifugation (24). Hepatocyte viability was > 95% as measured by trypan blue dye exclusion. From 5×10^5 to 1×10^6 hepatocytes were transplanted into a number of 10-18 day old uPA/RAG-2 mice by intrasplenic injection (24).

Repopulation with uninfected woodchuck hepatocytes is described in detail in Example 10 below.

Example 2

Screening for Normalized Serum Markers in Mice with Transplanted Hepatocytes

To screen for the survival and growth of the

transplanted woodchuck hepatocytes, sera of mice which received transplanted hepatocytes were analyzed for total protein, albumin, bilirubin, alanine aminotransferase activity (ALT), and aspartate aminotransferase activity (AST) in a standard automated clinical analyzer (Technicon Chem-1, San Francisco, CA). Normal serum markers in transplanted mice would indicate that the transplanted hepatocytes had restored normal liver function to the uPA/RAG2 mice.

Recipient and control mice were tested. Fifty milliliters of blood was collected from the retroorbital orifice and this was allowed to coagulate. Serum was extracted and injected directly into the automated analyzer to determine values. The blood markers of uPA/RAG-2 mice with chimeric livers containing woodchuck hepatocytes were found to be similar as compared to control uPA/RAG-2 mice without woodchuck hepatocytes (Table 2).

TABLE 2

Serum Parameters in uPA/RAG2 Mice

Mouse Colony Accession Number	351	457	496	969
Woodchuck Hepatocytes	[-] ¹	[-]	[+] ²	[+]
Total Protein (g/dl)	4.4	4.0	4.6	4.2
Albumin (g/dl)	2.6	2.4	2.8	2.6
AbT (u/l)	118	104	112	124
AST (u/l)	140	124	139	154
Bilirubin (mg/dl)	0.2	0.2	0.3	0.2

1[-] Denotes no transplantation

2[+] Denotes transplantation with xenogenic woodchuck
hepatocytes

In addition, partial hepatectomies in chimeric mice were performed under tribromoethanol-anesthesia (Aldrich, Milwaukee, Wisconsin) with approved protocols (25). The uPA/RAG-2 mice with chimeric livers containing woodchuck hepatocytes were clinically healthy and the livers appeared normal in respect to color, size, and liver weight to body weight ratios at sacrifice.

Example 3

Detection of Woodchuck and Mouse Albumin in Serum

The presence of serum albumin was tested as follows:
 5 $5\text{ }\mu\text{g}$ of total serum proteins were solubilized (26), boiled, and
 subjected to electrophoresis through an SDS-PAGE. Proteins
 resolved in 7.5% gels were fixed and stained with Coomassie
 Blue. SDS-PAGE showed that mouse and woodchuck serum albumin
 migrated differently (Figure 1). In chimeric uPA/RAG-2 mice,
 three months after woodchuck hepatocyte transplantation, this
 10 assay demonstrated the presence of both woodchuck and mouse
 serum albumin.

Example 4

Measurement of Woodchuck Hepatocyte Repopulation

15 To directly demonstrate the presence of woodchuck
 hepatocytes in chimeric uPA/RAG-2 mouse livers, DNAs extracted
 from recipient livers were hybridized with a total woodchuck
 genomic probe which detects only highly repeated sequences in
 the woodchuck genome (Figure 2A). Genomic DNAs were extracted
 20 from frozen liver and used for Southern blot analysis as
 previously described (27, 28). For detecting woodchuck genomic
 DNA in transplanted uPA/RAG-2 mouse livers, 150 ng (*Pvu II*
 digested) woodchuck DNA was used for a ^{32}P -labeled random
 genomic probe. Blots were hybridized under high stringency
 25 conditions (29) at 45°C for 2 hrs. To estimate the extent of
 uPA/RAG-2 mouse liver repopulation with woodchuck hepatocytes,
 we hybridized test mixtures of woodchuck and mouse genomic DNAs
 in various proportions as controls (Figure 2A, lanes 1-5).
 Lanes 1-4 present mixtures of genomic woodchuck liver DNA and
 30 untransplanted uPA/RAG-2 mouse genomic liver DNA with signals
 reflecting: 100%, 50%, 20%, and 1%, woodchuck hepatocyte DNA,
 respectively. Lane 5 shows 100% (untransplanted) uPA/RAG-2
 mouse DNA. Lane 6 shows that woodchuck DNA was undetectable in
 the spleen of transplanted uPA/RAG-2 mice.

35 DNAs from five liver lobes of a chimeric uPA/RAG-2

mouse transplanted with WHV-positive woodchuck hepatocytes (#496) showed the presence of WHV DNA in varying amounts. (Figure 2A, lanes 7-11). The data show that transplanted woodchuck hepatocytes were present in abundance in all liver lobes varying from approximately 30% to >95%.

Example 5

WHV DNA Replication and Persistence in Chimeric Mouse Liver

Chimeric mice transplanted with WHV-positive woodchuck hepatocytes were tested to determine if the repopulated livers supported WHV replication. Total genomic liver DNA of a representative chimeric recipient mouse repopulated with WHV infected woodchuck hepatocytes (#496) was analyzed for WHV DNA by hybridizing a Southern blot with a genome length 3.3 kb WHV-DNA ³²P-labeled probe (29). Lane 1 shows control non-transplanted uPA/RAG-2 mouse liver DNA; lane 2 shows DNA from a chimeric uPA/RAG-2 mouse liver transplanted with WHV-positive woodchuck hepatocytes; and lane 3 shows DNA from the donor woodchuck liver. Open circular (OC) WHV DNA, replicative DNA forms (RF), and covalently closed circular (CCC) WHV DNA match the profile of WHV DNA from the donor woodchuck (#2765) (Figure 2B, lanes 2 and 3). SS is single stranded DNA.

Example 6

Detection of WHx and WHc Proteins in Chimeric Mice

Woodchuck hepatitis virus protein WHx was immunoprecipitated from liver extracts with a rabbit WHx antiserum and subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) as previously described (30). For the detection of WHV core protein, 20 µg of total cell extracts were solubilized (26), boiled, and separated by SDS-PAGE.

Transblots of the SDS-PAGEs were probed with either WHx-antiserum (1: 1,000 dilution) or WHc-antiserum (1:5,000 dilution) and binding was detected by the enhanced

chemiluminescence (ECL) system (30) (Amersham. Arlington Heights, Illinois).

WHx proteins were present in chimeric mouse #496 liver. Figure 2C shows uPA/RAG-2 mouse liver (lane 1); chimeric uPA/RAG-2 mouse liver transplanted with WHV-positive woodchuck hepatocytes (lane 2); and donor woodchuck liver (lane 3).

WHc proteins were also present in chimeric mouse #496 liver. Figure 2D shows uPA/RAG-2 mouse (lane 1); chimeric uPA/RAG-2 mouse transplanted with WHV-positive woodchuck hepatocytes (lane 2); and donor woodchuck (lane 3).

Example 7

Detection of WHsAg in Woodchuck and uPA/RAG-2 Mouse Sera

Mouse serum was tested for the presence of WHsAG. For immunoblotting of WHsAg, proteins were resolved in SDS-PAGE, electrotransferred, probed with a rabbit antiserum against WHsAg (WHs-antiserum) (1:1,000 dilution), and visualized by ECL. Figure 2E shows immunoblotting with WHs-antiserum of uPA/RAG-2 mouse sera (#249), uPA/RAG-2 mouse sera transplanted with WHV-positive woodchuck hepatocytes (#496, 969, 1063, 1418). Lane 1: WHV-positive woodchuck serum.

Example 8

WHV RNA Detection

Analysis of WHV RNA in chimeric mouse #496 liver was analyzed by Northern blot performed using 15 ug of total RNA from the mouse #496 liver RNA. The blot was hybridized with a ³²P total WHV, DNA genome probe. The blot revealed the expected major mRNA species of 3.6 and 2.4 Kb corresponding to the pregenome mRNA and the major envelope protein RNAs.

Example 9

Histological Studies

Serial cryostat sections of the chimeric uPA/RAG-2 mouse livers repopulated with WHV infected woodchuck

hepatocytes, as well recipient uPA/RAG-2 mice without transplants, were examined by hematoxylin & eosin (H&E) staining, dipeptidyl peptidase IV (DPPIV) enzyme activity (31) and immunohistochemistry with a rabbit WHc-antiserum against woodchuck hepatitis core antigen (WHcAg). To investigate the growth pattern of woodchuck hepatocytes in uPA/RAG-2 mouse liver, we performed immunohistochemistry using an antibody directed against WHV core antigens (anti-WHcAg).

For immunolabeling, sections were fixed in 4% paraformaldehyde, incubated with WHc-antiserum (diluted 1:250 in PBS containing 5% sheep serum) at room temperature and subsequently incubated with the Cy3-conjugated sheep anti-rabbit IgG antibody (Sigma, St. Louis, MO) diluted 1:200 in phosphate buffered saline (PBS) with 5% sheep serum at room temperature. Finally, slides were mounted in 40 mg n-propylgallate/ml in 90% glycerol, 10% 0.5 M sodium carbonate. pH 8, for viewing under a fluorescence microscope.

WHV-positive woodchuck hepatocytes had seeded the liver and grown in a nodular pattern within the framework of the preexisting liver with maintenance of the liver cord structure as can be detected by the specific red fluorescence staining signal in the chimeric liver (Figure 3A). A nodule containing transplanted WHV-positive woodchuck hepatocytes (lighter area, rhodamine light) and host mouse hepatocytes that presumably deleted the uPA transgene (darker stained area) (200x). Untransplanted mice did not show any positive staining.

Integration of the woodchuck hepatocytes into the liver architecture was evaluated by histochemistry for the enzyme DPPIV which is localized in bile canaliculi of hepatocytes (31). Mouse hepatocytes appeared smaller and DPPIV-positive areas were therefore more compact. In contrast, areas containing woodchuck cells showed greater spacing between DPPIV-positive domains due to larger cell sizes. In chimeric uPA/RAG-2 mouse livers containing woodchuck and mouse hepatocytes we observed networks of DPPIV positive bile

canaliculi between adjacent mouse and woodchuck hepatocytes (Figure 3B). Bile canaliculi (200X) are visible between mouse hepatocytes (darker staining) and transplanted woodchuck hepatocytes (lighter staining). Nuclei are counterstained with hematoxilin. The presence of woodchuck hepatocytes in those sections was confirmed by performing immunohistochemistry using a WHc-antiserum in serial sections from uPA/RAG-2 mouse liver tissues.

Interestingly, despite expression of WHV proteins in transplanted woodchuck hepatocytes, we did not observe any hepatocellular infiltration with inflammatory cells. The uPA/RAG-2 mice are of course deficient in T and B lymphocytes, however, no evidence was found of infiltration with granulocytes or macrophages.

Example 10

Detection of WHV DNA in Serum

Woodchucks were anesthetized with ketamine (Fort Dodge Laboratories, Fort Dodge, Iowa) and xylazine (Bayer, Shawnee Mission, Kansas) and blood was collected from the femoral vein. Blood was drawn from the tail vein in mice and woodchuck and mouse sera were dot blotted onto a nylon membrane (32), hybridized with a ^{32}P -labeled WHV-DNA probe (29) and the number of WHV DNA molecules were quantitated by scanning densitometry. Serial dilutions of known amounts of a plasmid containing one copy of WHV DNA served as a standard.

WHV DNA in the serum of chimeric uPA/RAG-2 mice repopulated with infected woodchuck hepatocytes became detectable only after completion of liver regeneration with a lag period of viremia of 8-12 weeks after transplantation. WHV DNA titers stabilized at a level of approximately 5×10^8 viral genomes per ml in the transplanted mouse #496 as compared to 1×10^9 WHV genomes per ml in the donor woodchuck (data not shown). In other chimeric uPA/RAG-2 mice, WHV titers of up to 1×10^{11} virions/ml mouse serum were detected (Figure 4).

Each line in the Figure shows individual uPA/RAG-2 mice containing WHV-secreting woodchuck hepatocytes. Black arrows mark starting point and withdrawal of agents. Time points mark the collection of serum samples. The dashed line represents the threshold of sensitivity for the Dot blot analysis.

In virus particles isolated from the serum of transplanted uPA/RAG-2 mice, viral DNA could be isolated and it migrated on Southern blots in a similar fashion to the WHV DNA from the donor woodchuck.

Example 11

Infection of Naive, Uninfected Woodchuck Hepatocytes in Chimeric Mice

To investigate whether naive woodchuck hepatocytes could be infected with WHV in uPA/RAG-2 mice, hepatocytes from an adult uninfected woodchuck were transplanted into the liver of uPA/RAG-2 mice according to the methods of Example 1. After completion of liver regeneration, three months following transplantation, four chimeric uPA/RAG-2 mice were subjected to a liver biopsy and the presence of woodchuck hepatocytes was confirmed by Southern blot analysis according to the methods of Example 1.

Subsequently, these chimeric uPA/RAG-2 mice were infected with either 10 μ l i.m. of a WHV-positive woodchuck serum, containing approximately 1×10^9 virions/ml, or with 10 μ l i.m. of WHV containing serum from uPA/RAG-2 mouse #496 (5×10^8 virions/ml). The establishment of productive infection was monitored by serum dot blot analysis for WHV DNA. WHV DNA became detectable at four weeks after infection. Southern blot analysis of chimeric uPA/RAG-2 mouse liver DNAs hybridized with a WHV DNA genomic probe demonstrated the presence of open circular and replicative WHV DNA forms. The serum WHV virion levels have remained stable for an additional ten months in the infected animals confirming the persistence of WHV infection in chimeric uPA/RAG-2 mice wherein the hepatocytes were infected

after transplantation.

Example 12

Antiviral Studies in WHV Replicating Chimeric uPA/RAG-2 Mice

To confirm the usefulness of the chimeric uPA/RAG-2 mouse model for studying hepadnaviral replication, modulation of WHV replication with either interferon-alpha or dexamethasone treatment was investigated. Three chimeric uPA/RAG-2 mice were chosen for this experiment, #1418 contained hepatocytes from a chronic WHV carrier, while mice #1063 and #1098 were transplanted with naive woodchuck hepatocytes and infected with WHV-containing sera as described in Example 11. All mice showed a constant level of viral replication before drug administration (See Figure 4).

In order to test the effects of antiviral compounds on the replication of WHV DNA in infected livers, 135 IU/g body weight of Interferon-alpha-2b (Schering, USA) or 27 ng/g body weight Dexamethasone (Fujisawa, Deerfield, IL) were administered to mice intramuscularly daily for 15 consecutive days.

Dexamethasone significantly upregulated viral replication. After withdrawal of dexamethasone, the level of WHV replication remained at higher levels compared with pretreatment levels. In contrast, treatment with interferon-alpha downregulated WHV replication in mouse #1063 by greater than four logs to non-detectable levels in serum dot blots after 15 days. However, upon withdrawal of interferon-alpha, WHV replication rebounded to levels higher than pretreatment WHV levels. Mouse #1418, with higher WHV pretreatment levels than mouse #1063, showed only a limited response to interferon-alpha treatment, although with a rebound effect upon viral replication similar to mouse #1063 after drug withdrawal.

The data show a transient reduction in WHV DNA in sera after 15 days of interferon-alpha treatment as well as enhanced WHV replication by stimulation of the Glucocorticoid

Responsive Element with dexamethasone. The immediate rebound of viral replication after withdrawal of interferon-alpha strongly suggests that WHV DNA was not cleared from woodchuck hepatocytes and that woodchuck hepatocytes were not eliminated as a result of interferon-alpha treatment. The effectiveness of human interferon-alpha against WHV suggests that other human and murine reagents will cross react with their woodchuck homologues. The discussion of the possible mechanisms involved herein are not to be construed as limiting.

Example 13

Heterogeneous Precancerous and Malignant Phenotypes of Transplanted Woodchuck Hepatocytes in Chimeric uPA/RAG-2 Mice

The phenotypes of transplanted woodchuck hepatocytes in relation to hepatocytes present in the donor woodchuck were compared. In the chronic carrier woodchuck #2765, precancerous altered hepatic foci (AHF) were rare and comprised at the most, 1% of the total number of hepatocytes, according to H&E staining of liver sections (Figure 5A, 200X). In contrast, nearly all of the nodules in the corresponding chimeric uPA/RAG-2 mouse livers had a distinct AHF phenotype (Figure 5B, 200X) which was absent in control nontransplanted mouse livers. The hepatocytes present in the AHFs of chimeric uPA/RAG-2 mice (Figure 5D, 1000x) were clearly different from normal woodchuck (Figure 5C, 1000X) or normal mouse hepatocytes in that they contained large nuclei with very prominent nucleoli.

Also detected were a primary hepatocellular carcinoma (HCC) (Figure 5F, 200X) and a cholangiocarcinoma (Figure 5H, 200X) derived from WHV-infected woodchuck cells after transplantation into a uPA/RAG-2 mouse liver. The donor cells came from a chronic WHV carrier woodchuck (#4940) which had developed three HCCs and a cholangiocarcinoma (Figures 5E and 5G, respectively, each at 200X). HCC and cholangiocarcinoma, respectively, came from a woodchuck (#4940) chronically infected with WHV (200x each).

Figure 6A provides Southern blot analysis of HCC tumor DNA from a chimeric uPA/RAG-2 mouse liver, hybridized with woodchuck genomic DNA (6A lanes 3 and 4) or WHV DNA probe, (6A, lanes 1 and 2). The Figure shows that woodchuck DNA was detectable in the tumor arising in the uPA/RAG-2 chimeric mouse (lane 3, with lane 4 as a negative control). In addition, unique WHV DNA integrations were identified in the DNA from the same tumor tested in lane 3 using a WHV DNA probe (lane 2, with lane 1 as negative control). Figure 6B demonstrates that the WHV DNA integrations present in the chimeric mouse livers were different from the WHV DNA integrations in the original donor woodchuck tumor DNA samples because the WHV DNA integrations in the donor woodchuck tumor were different sizes than those present in the chimeric uPA/RAG2 mouse liver tumor (compare 6B lanes 1-3 versus 6A lane 2). These data clearly demonstrated that a new HCC developed in the chimeric mouse liver showing that liver tumor genesis occurs in lab transplanted livers. In this model, a transplanted woodchuck hepatocyte may have obtained a tumorigenic mutation during growth in the chimeric liver leading to malignant transformation. The discussion of the possible mechanisms involved herein are not to be construed as limiting.

Example 14

Repopulation of UPA/RAG-2 mouse livers with human hepatocytes followed by *in vivo* infection with HBV.

Human donor livers or liver segments that were denied for human liver transplantation were used to obtain primary human hepatocytes to be used in the liver cell transplantation procedures as outlined in Example 1. Briefly, primary human hepatocytes were isolated according to the two-step collagenase perfusion method followed by differential and percoll gradient centrifugation (24). Hepatocyte viability was >80% as measured by trypan blue dye exclusion. 1×10^6 human hepatocytes were transplanted into a number of 10 - 14 day old UPA/RAG-2 mice by

intrasplenic injection. Transplanted human hepatocytes were detectable in the perisinusoidal area 24 hours after transplantation. Normal adult human hepatocytes proliferated and were found to integrate into the recipient mouse liver cord structure, where, at 6 weeks after transplantation, they had reconstituted approximately 10% of the UPA/RAG-2 mouse livers. Human serum albumin was detected in mouse sera by PAGE/Western blot analysis.

The UPA/RAG-2 chimeric mice containing human hepatocytes were infected with human HBV as shown by the presence of hepatitis B surface antigen in the chimeric mouse serum by ELISA and immunoblotting. HBV core-protein was detected histochemically in serial cryostat sections of UPA/RAG-2 mouse livers. Quantitative PCR demonstrated viral titers up to 1×10^9 virions/mL 6 weeks after transplantation. No inflammatory host immune response was observed in the chimeric livers of the HBV-replicating mice.

The foregoing examples demonstrate experiments performed and contemplated by the present inventor in making and carrying out the invention. It is believed that these examples disclose various techniques which serve to demonstrate the practice of and usefulness of the invention. It will be appreciated by those skilled in the art that various changes may be made in the embodiments and techniques exemplified without departing from the scope of the invention.

REFERENCES

1. Ganem, D., and Varmus, H.E. (1987) *Annu. Rev. Biochem.* 56:651-693.
2. Buendia, M.A. (1992) *Adv. Cancer Res.* 59:167-226.
3. B.S. Blumberg. (1997) *Proc. Natl. Acad. Sci. USA* 94:7121-7125.
4. Rogler, C.E. (1991) *Curr. Top. Microbiol. Immunol.* 168:103-141.
5. Fried, M.W. (1996) *Medical Clinics of North America* 80:957-971.
6. Perillo, R.P., & Mason, A.L. (1994) *Gastroenterology Clinics of North America* 23:581-601.
7. Perillo, R.P., Schiff, E.R., Davis, G.L., Bodenheimer, H.C., Lindsay, K et al. (1990) *NEJM* 323:295-301.
8. Haria, M., & Benfield, P. (1995). *Drugs* 50:873-896.
9. Yamashita, Y., Koike, K., Takashi, M., & Matsuda, S. (1988) *Microbiol Immunol* 32: 1119-1126.
10. Nagahata, T., Araki, K., Yamamura, K.I., & Matsubara, K. (1992) *Antimicrobial Agents Chemother* 36:2042-2045.
11. Chisari, F.V., & Ferrari, C. (1995) *Annu. Rev. Immunol.* 13:29-60.
12. Chisari, F.V. (1996) *Curr Topics Microbiol Immunol* 206:150-173.
13. Guidotti, L.G., Ando, K., Hobbs, M.V., Ishikawa, T., Runkel, L., Schreiber, R.D. & Chisari, F.V. (1994) *Proc. Natl. Acad. Sci. USA* 91:3764-3768.
14. Guidotti, L.G., Ishikawa, T., Hobbs, M.V., Matzke, B., Schreiber, R., & Chisari, F.V. (1996) *Immunity* 4:25-36.
15. Gupta, S., Rajvanshi, P., Bhargava, K.K., & Kerr, A. (1996) *Prog Liv Dis* 14:199-222.
16. Sandgren, E.P., Palmiter, R.D., Heckel, J.L., Daugherty, C.C., Brinster, R.L., & Degen, J.L. (1991) *Cell* 66:245-

- 256.
17. Rhim, J.A., Sandgren, E.P., Degen, J.L., Palmiter, R.D., & Brinster, R.L. (1994) *Science* 263:1149-1152.
 18. Rhim, J.A., Sandgren, E.P., Palmiter, R.D., and Brinster, R.L. (1995) *Proc. Natl. Acad. Sci. USA* 92:4942-4946.
 19. Roggendorf, M., & Tolle, T.K. (1995) *Intervirology* 38:100-112.
 20. Korba, B.E., Cote, P.J., Wells, F.N., Baldwin, B., Popper, H., Purcell, R.H., Tennant, B.C., & Gerin, J.L. (1989). *J Virol* 63:1360-70.
 21. Tennant, B.C., & Gerin, J.L. (1994) in *The Liver. Biology and Pathobiology*, eds. Arias, I.M., Boyer, J.L., Fausto, N., Jakoby, W.B., Schachter, D., & Shafritz, D.A. (Raven Press, New York) pp 1455-1469.
 22. Shinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., Stall, A.M., & Alt, F.W. (1992) *Cell* 68:855-867.
 23. Horton, R.M., Karachunski, P.I., & Conti-Fine, B.M. (1995) *Bio Techniques* 19:690-691.
 24. Gupta S., Vemuru. R.P., Lee, C.D., Yemeni, P., Aragona, E., & Burk, R.D. (1994) *Human Gene Ther* 4:249-257.
 25. Vemuru, R.P., Aragona, E., & Gupta, S. (1992) *Hepatology* 16:968-73.
 26. Laemmli, U.K. (1970). *Nature* 227:680-685.
 27. Gong, S.S., Jensen, A.D., & Rogler, C.E. (1996). *J. Virol.* 70:2000-2007.
 28. Petersen, J., Buerkle, A., Zhang, L., & Rogler, C.E. (1997) *J. Virol.* 71:5455-5463.
 29. Ogston, C.W., Jonak, G.J., Rogler, C.E., Astrin, S.M., & Summers, J. (1982) *Cell* 29:385-394.
 30. Dandri, M., Schirmacher, P., & Rogler, C.E. (1996). *J. Virol.* 70:5246-5254.

31. Rajvanshi, P., Kerr, A., Bhargava, K.K., Burk, R.D., & Gupta, S. (1996) *Hepatology* 23:482-496.
32. Scotto, J., Hadchouel, M., Hery, C., Yvart, Y., Tiollais, P., & Brechot, C. (1983) *Hepatology* 3:279-284.

1
1

WHAT IS CLAIMED

1 1. A method of making a chimeric mouse, comprising:
2 a. creating an immunetolerant mouse which has
3 a degenerated liver; and
4 b. transplanting xenogenic mammalian
5 hepatocytes capable of being infected with at least one
6 compatible mammalian hepatitis virus to repopulate the
7 parenchyma of the degenerated liver.

2. The method of claim 1, which comprises infecting
the xenogenic mammalian hepatocytes with hepatitis virus prior
to said transplanting.

3. The method of claim 1, which comprises infecting
the xenogenic mammalian hepatocytes with hepatitis virus
following said repopulation.

4. The method of claim 1, which comprises selecting
the xenogenic mammalian hepatocytes from the group consisting
of human, chimpanzee, baboon, wooly monkey, ground squirrel,
and woodchuck hepatocytes.

5. The method of claim 1, wherein the compatible
mammalian hepatitis virus is at least one of a compatible
mammalian hepatitis A virus, hepatitis C virus, hepatitis D
virus coinfecting with hepadnavirus, hepatitis E virus,
hepatitis F virus or hepadnavirus.

1 6. The method of claim 1, wherein the
2 immunetolerant mouse which has a degenerated liver is created
3 by:
4 a. crossing a hemizygous or homozygous
5 urokinase-type plasminogen activator (uPA) transgenic mouse
6 with a homozygous Recombination Activation Gene 2 (RAG-2)

7 knockout mouse to generate F1 uPA hemizygous, RAG-2 hemizygous
8 sibling mice; and

9 b. crossing the F1 mouse to another sibling F1
10 mouse or to a RAG2 homozygous mouse to generate a uPA
11 hemizygous or homozygous, RAG2 homozygous (uPA/RAG2) F2 mouse.

7. The method of claim 6, wherein the xenogenic mammalian hepatocyte is from a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

8. A chimeric mouse model system for hepatitis comprising an immunetolerant mouse having a degenerated liver parenchyma repopulated with transplanted xenogenic mammalian hepatocytes that are capable of being infected with a compatible mammalian hepatitis virus.

9. The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes are infected with hepatitis virus prior to said transplantation.

10. The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes are infected with hepatitis virus following said repopulation.

11. The chimeric mouse model system of claim 8, wherein the xenogenic mammalian hepatocytes is a member selected from the group consisting of human, chimpanzee, baboon, wooly monkey, ground squirrel, and woodchuck hepatocytes.

12. The chimeric mouse model system of claim 8, wherein the compatible mammalian hepatitis virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

13. The chimeric mouse model system of claim 8, wherein the immunetolerant mouse having degenerated liver parenchyma is hemizygous or homozygous for the urokinase-type plasminogen activator (uPA) transgene and is homozygous for the Recombination Activation Gene 2 (RAG-2) knockout gene.

14. The chimeric mouse model system of claim 13, wherein the xenogenic mammalian hepatocyte is derived from a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

15. A method for screening a test compound for anti-viral activity, comprising:

- a. administering said test compound to an immunetolerant chimeric mouse which has a degenerated liver parenchyma repopulated with transplanted xenogenic mammalian hepatocytes and wherein the xenogenic mammalian hepatocytes are infected with at least one compatible mammalian virus; and
- b. assaying the level of replication of the virus.

16. The method of claim 15, wherein the mammalian virus is at least one hepatitis virus.

17. The method of claim 15, which comprises comparing the level of viral replication in said mouse and in a control mouse which has not been administered the test compound.

18. The method of claim 15, which comprises infecting the xenogenic mammalian hepatocytes with the compatible mammalian virus prior to said transplanting.

19. The method of claim 16, which comprises infecting the xenogenic mammalian hepatocytes with the

compatible mammalian virus following said repopulating step.

20. The method of claim 15, which comprises selecting the xenogenic mammalian hepatocyte from the group consisting of human, chimpanzee, baboon, wooly monkey, ground squirrel, and woodchuck hepatocytes.

21. The method of claim 15, wherein the compatible mammalian virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

22. The method of claim 15, wherein the immunetolerant mouse which has a degenerated liver is hemizygous or homozygous for the urokinase-type plasminogen activator (uPA) transgene and homozygous for the Recombination Activation Gene 2 (RAG-2) knockout gene.

23. The method of claim 22, wherein the xenogenic mammalian hepatocyte is derived from a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

24. The method of claim 15, wherein the antiviral compound is a member selected from the group consisting of interferons, cytokines, interleukins, growth factors, hormones, nucleoside analogues, and antisense DNA/RNA.

25. A method for screening a test compound for anti-cancer activity, comprising:

a. administering said test compound to an immunetolerant chimeric mouse which has degenerated liver parenchyma repopulated with transplanted xenogenic mammalian hepatocytes and wherein the xenogenic mammalian hepatocytes are

7 infected with at least one compatible mammalian hepatitis
8 virus; and

9 b. assaying the mice for the development of
10 hepatocellular carcinoma in said mice.

26. The method of claim 25, which comprises comparing the presence of unique viral DNA integrations in the liver of said mouse and in a control mouse which has not been administered the test compound.

27. The method of claim 25, wherein the chimeric mouse has precancerous or malignant cancerous hepatic tissue and wherein the development of hepatocellular carcinomas is assayed by monitoring for the prevention of the development of cancerous tissue from precancerous tissue or the amelioration of the malignant cancerous tissue.

28. The method of claim 27, which comprises comparing the assay in the chimeric mouse with the same assay carried out in a control mouse which has not been administered the test compound.

29. The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes with a hepatitis virus prior to said transplantation step.

30. The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes with hepatitis virus prior to said transplanting step.

31. The method of claim 25, which comprises infecting the xenogenic mammalian hepatocytes are infected with hepatitis virus following said repopulating step.

32. The method of claim 25, which comprises

selecting the xenogenic mammalian hepatocyte from the group consisting of human, chimpanzee, baboon, wooly monkey, ground squirrels and woodchuck hepatocytes.

33. The method of claim 25, wherein the compatible mammalian hepatitis virus is at least one of a compatible mammalian hepatitis A virus, hepatitis C virus, hepatitis D virus coinfecting with hepadnavirus, hepatitis E virus, hepatitis F virus or hepadnavirus.

34. The method of claim 25, wherein the immunetolerant mouse which has a degenerated liver is hemizygous or homozygous for the urokinase-type plasminogen activator (uPA) transgene and homozygous for the Recombination Activation Gene 2 (RAG-2) knockout gene.

35. The method of claim 33, wherein the xenogenic mammalian hepatocyte is derived from a woodchuck and the compatible mammalian hepatitis virus is Woodchuck Hepatitis Virus (WHV).

36. The method of claim 25, wherein the anticancer compound is a member selected from the group consisting of interferons, cytokines, interleukins, growth factors, hormones, nucleoside analogues, and antisense DNA/RNA.

ABSTRACT






A method is provided for repopulating degenerated of immunetolerant mice which lack mature B and T lymphocytes with xenogenic mammalian hepatocytes, particularly primate hepatocytes to generate chimeric mice. In addition, a method of generating a human hepatitis virus-infected chimeric mouse is provided. A preferred xenogenic primate hepatocyte is derived from human, chimpanzee or baboon. These chimeric mice are useful in the investigation of host and viral mechanisms determining hepadnaviral persistence and hepatocarcinogenesis. Methods for monitoring the development of hepatitis and hepatocellular carcinoma as well as methods for testing and screening anti-viral and anti-cancer compounds with this model system are also provided.

1 2 3



Figure 1

Figs 2A-E






Fig 3 B




Fig. 3 A













Fig. 4



Figs. 5A-H



Figs 6A-B

DECLARATION AND POWER OF ATTORNEY
(Continuation-In-Part Application)

As a below named inventor, I declare that:

1. The information given herein is true, and I believe that I am the original, first and sole inventor (if only one name is listed below), or a joint inventor (if plural inventors are named below), of the invention entitled:

CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL
HEPATOCELLULAR CARCINOMA IN MOUSE REPOPULATED LIVERS

which is described and claimed in:

- ☒ the attached specification or
- ☐ the specification in application
Serial No. ,
Filed:
(for declaration not accompanying application);

2. This application in part discloses and claims new subject matter as well as subject matter disclosed in my earlier-filed application(s)

Serial No. 09/156,892
Filed: 09/18/98
For: CHRONIC HEPATITIS VIRUS INFECTION
AND CLONAL HEPATOCELLULAR CARCI-
NOMA IN MOUSE REPOPULATED LIVERS

3. I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 C.F.R. §1.56, including such material information which occurred between the filing date of said earlier application and the filing date of this application.

4. I have reviewed and understand the contents of the specification, including the claims, as amended by any amendment specifically referred to herein.

5. As to the subject matter of this application which is common to said earlier application I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our

invention thereof, or more than one year prior to said earlier application or in public use or on sale in the United States of America more than one year prior to said earlier application; said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to said earlier application. As to the subject matter of this application which is common to said earlier application, I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed as to the common subject matter are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

COUNTRY APPLICATION NO. DATE OF FILING

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

COUNTRY APPLICATION NO. DATE OF FILING

6. As to the new subject matter of the present application which is not common to said earlier application I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in a printed publication in any country before my or our invention thereof or more than one year prior to the date of this application, or in public use or on sale in the United States of America more than one year prior to

the date of the present application, and said matter has not been patented or made the subject of an inventor's certificate in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application. As to the new subject matter of the present application which is not common to said earlier application, I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed for the new subject matter are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
----------------	------------------------	-----------------------

ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
----------------	------------------------	-----------------------

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Marc S. Gross #19,614, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, David R. Francescani #25,159, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

DIRECT TELEPHONE CALLS TO:

Anne E. Zitron, Ph.D.
212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: Rogler FIRST NAME: Charles MIDDLE NAME: E.

CITY: Hawthorne STATE OR FOREIGN COUNTRY: New York COUNTRY OF CITIZENSHIP: USA

POST OFFICE ADDRESS: 525 Warren Avenue CITY: Hawthorne STATE OR COUNTRY: New York ZIP CODE: 10532

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR: _____ DATED:

::ODMA\WORLDOX\M:\0342\1D888\KRJ2751.WPD